Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China

Wang, Zhongliang; Yang, Binyao; Li, Qianwen; Liu, Wen; Zhang, Ruiguang

doi:10.1093/cid/ciaa272

Cited by 929 publications

(954 citation statements)

References 27 publications

Supporting

Mentioning

865

Contrasting

Unclassified

Order By: Relevance

“…Fever, cough, fatigue, and myalgia are usually the main symptoms. The expression of COVID-19 ILI seems non-specific; no specific symptom can lead to suspecting a case without any notion of exposure [2][3][4][5][6][7]. A major French cluster of COVID-19 began on March 1, 2020 in the city of Mulhouse, France (less than 30 miles from our hospital).…”

Section: Introductionmentioning

confidence: 99%

Features of anosmia in COVID-19

Klopfenstein

Kadiane-Oussou

Toko

et al. 2020

Médecine et Maladies Infectieuses

374

377

View full text Add to dashboard Cite

Page 2 of 11 J o u r n a l P r e -p r o o f Background. Medical publications about anosmia with COVID-19 are scarce. We aimed to describe the prevalence and features of anosmia in COVID-19 patients. Methods. We retrospectively included COVID-19 patients with anosmia between March 1 andMarch 17, 2020. We used SARS-CoV-2 real time PCR in respiratory samples to confirm the cases.Results. Fifty-four of 114 patients (47%) with confirmed COVID-19 reported anosmia. Mean age of the 54 patients was 47 (±16) years; 67% were females and 37% were hospitalized. The median Charlson comorbidity index was 0.70 (±1.6 [0-7]). Forty-six patients (85%) had dysgeusia and 28% presented with pneumonia. Anosmia began 4.4 (±1.9 [1-8]) days after infection onset. The mean duration of anosmia was 8.9 (±6.3 [1-21]) days and 98% of patients recovered within 28 days. Conclusions.Anosmia was present in half of our European COVID-19 patients and was often associated with dysgeusia.

show abstract

Section: Introductionmentioning

confidence: 99%

Features of anosmia in COVID-19

Klopfenstein

Kadiane-Oussou

Toko

et al. 2020

Médecine et Maladies Infectieuses

374

377

View full text Add to dashboard Cite

show abstract

“…The CRP level in 243 virus-induced CRS remains to be determined. Most studies suggested that elevated 244 CRP levels were associated with severe COVID-19 [37,53,54], with a few exceptions 245 [35]. Nevertheless, future studies on biomarkers are needed for the purpose of risk 246 stratification and therapeutic effect monitoring.…”

mentioning

confidence: 99%

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Liu

Zhou

et al. 2020

Journal of Autoimmunity

654

648

View full text Add to dashboard Cite

“…Disease severity at presentation was assessed by the SpO2 as the sole criteria, with a cutoff of 90%. Among these 69 patients, four had a history of malignancy of whom only one patient presented with an SpO2 <90% (14).…”

Section: Epidemiological Clinical Pathological and Radiographic Feamentioning

confidence: 99%

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Moujaess

Kourié

Ghosn

2020

Critical Reviews in Oncology/Hematology

186

194

View full text Add to dashboard Cite

The novel coronavirus, also known as SARS-Cov-2 or COVID-19 has become a worldwide threat and the major healthcare concern of the year 2020. Cancer research was directly affected by the emerging of this disease. According to some Chinese studies, cancer patients are more vulnerable to COVID-19 complications. This observation led many oncologists to change their daily practice in cancer care, without solid evidence and recommendations. Moreover, the COVID-19 manifestations as well as its diagnosis are particular in this special population. In this review paper we expose the challenges of cancer management in the era of SARS-CoV-2, the epidemiological, clinical, pathological and radiological characteristics of the disease in cancer patients and its outcomes on this population. Finally, we focus on strategies that are followed in cancer management with review of national and international guidelines. J o u r n a l P r e -p r o o f electronic search of the literature was conducted in the PubMed database until the 5th of April 2020. The following keywords with Boolean operators were used 'covid-19', 'novel coronavirus'and 'SARS-CoV-2' in combination with 'cancer', 'neoplasm', 'oncology' and 'malignancy'. A total of 223 articles were extracted. We included articles in English as well as articles in French because we are familiar with this language. Abstracts in English of articles in Chinese language were also J o u r n a l P r e -p r o o f 3 included. Duplicated articles and articles that were published before the era of SARS-Cov-2 (i.e., before December 2019) were excluded. Titles and abstracts of retrieved articles were screened for eligibility, and then entire texts were analyzed and 88 papers that respond to our objectives were included in this review. Our work is summarized in the PRISMA diagram below. ResultsOut of 88 articles, six were in French language and 19 were in Chinese language with English abstracts. Most of the papers consisted of short editorials, letters, correspondence or comments.Ten Cohort studies were identified (retrospective, prospective or cross-sectional analysis) as well as 9 case reports and one case series. Only four of the cohort studies exclusively included cancer patients. Of note, all cohort studies were conducted in China. Most of the reported cases originated from China and Italy.59% of the published papers originated from China and Italy (52 of 88). Seven works were multinational and the majority of them were multicontinental, issued in collaboration between researchers from Asia, Europe and the Americas. We identified one article originating from each of the following countries: Canada, India, Singapore, Spain and Saudi Arabia. The pie chart below

show abstract

Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China

Abstract: In this retrospective case series that included 69 adults in Wuhan, 29% of patients showed dyspnea and 20% of cases showed SpO2<90%. Patients with SpO2<90% had a significantly higher risk of death. Abidol showed initial therapeutic effect. ABSTRACT Background

Cited by 929 publications

References 27 publications

Features of anosmia in COVID-19

Features of anosmia in COVID-19

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Contact Info

Product

Resources

About